EUVIMEDEUVIMED entdecken
Crossref

Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus

Akira Yamamoto iD, Ken Kageyama, Atsushi Jogo, Etsuji Sohgawa iD, Ryuichi Kita, Sawako Uchida-Kobayashi, Shigekazu Takemura, Akihiro Tamori, Toshio Kaminou, Yukio Miki

British Journal of Radiology · 2025

DOI: 10.1093/bjr/tqaf112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Radiology, 2025. Verfasst von Akira Yamamoto und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Portal Vein, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To investigate the safety and long-term effectiveness of repeated ultraselective transarterial chemoembolization (rusTACE) using a 1.7-Fr-tip microcatheter in hepatocellular carcinoma (HCC) patients with portal vein tumour thrombus (PVTT).

Methods

This retrospective analysis includes HCC patients with PVTT treated with rusTACE between May 2014 and July 2022. A 1.7-Fr-tip microcatheter was used to perform rusTACE for ultraselective embolization of the tumour-feeding artery. Treatment was repeated at least 2 times within 2 months. Treatment responses, survival rates, adverse event, liver function, and tumour-feeding arteries were assessed.

Results

Twenty patients underwent rusTACE with a mean interval of 42 days between treatments. RusTACE was well-tolerated. Median survival time was 26.1 months, with 1-, 2-, 3-, and 5-year survival rates of 85.0%, 61.0%, 40.9%, and 24.6%, respectively. Complete response (CR) of PVTT was achieved in 75%. Among these, 35% maintained CR of PVTT throughout follow-up (mean, 25.0 months). Univariate analysis showed prognostic factors included Child–Pugh score 5, CR of PVTT, CR of systemic tumours at the end of rusTACE, and liver tumour burden <30%. In 17%, a peribiliary vascular plexus or communicating artery was identified as the tumour-feeding artery.

Conclusions

RusTACE is a safe and effective treatment option for HCC with PVTT in selected patients (Child–Pugh class A). RusTACE showed a high CR rate and long overall survival. The short interval between treatments and ultraselective embolization of tumour-feeding arteries contributed to favourable outcomes. Advances in knowledge RusTACE can be safely performed in HCC with PVTT and has a high local control rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPortal VeinChemoembolization, TherapeuticVenous ThrombosisHumansMaleFemaleRetrospective StudiesMiddle AgedAgedTreatment OutcomeAdultSurvival Rate

Stichwörter der Autor:innen

HCCPVTTconventional TACEsuperselective TACEultraselective TACE

Autor:innen und Institutionen

  • Department of Diagnostic and Interventional Radiology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
  • Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka 543-8555, Japan.
  • Department of Hepatology, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
  • Department of Frontier Life-Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka 545-8585, Japan.
  • Department of Hepatology, Kashiwara Municipal Hospital, Kashiwara 582-0005, Japan.
  • Department of Radiology, Tsukazaki Hospital, Himeji 671-1227, Japan.

ORCID-Profile: Akira Yamamoto, Etsuji Sohgawa

Zitieren

APA

Yamamoto, A., Kageyama, K., Jogo, A., Sohgawa, E., Kita, R., Uchida-Kobayashi, S., Takemura, S., Tamori, A., Kaminou, T., & Miki, Y. (2025). Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus. British Journal of Radiology. https://doi.org/10.1093/bjr/tqaf112

Vancouver

Yamamoto A, Kageyama K, Jogo A, Sohgawa E, Kita R, Uchida-Kobayashi S, et al. Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus. British Journal of Radiology. 2025. doi:10.1093/bjr/tqaf112

BibTeX
@article{Yamamoto2025,
  author = {Yamamoto, Akira and Kageyama, Ken and Jogo, Atsushi and Sohgawa, Etsuji and Kita, Ryuichi and Uchida-Kobayashi, Sawako and Takemura, Shigekazu and Tamori, Akihiro and Kaminou, Toshio and Miki, Yukio},
  title = {Repeated ultraselective transcatheter arterial chemoembolization for hepatocellular carcinoma with portal vein thrombus},
  journal = {British Journal of Radiology},
  year = {2025},
  doi = {10.1093/bjr/tqaf112}
}
Kostenlos starten →